VSCR Quality Charter
In order to fulfill the mission of VSCR a transparent and consistent system of quality assurance and -control is of elementary importance. VSCR is oriented to common and approved university standards for continuous professional development
On top of it VSCR fullfils the criteria of the published IMI*) Quality Criteria**):
- A formalised and transparent QA/QC policy that includes the following:
- University accreditation OR a suitable system for approving, monitoring and reviewing the training offered.
- A system for quality assurance of teaching staff.
- Regular review of the QA/QC process and demonstration that the training is further developed in light of this review.
- A set of documented criteria for individual modules, courses or course programmes that include the following:
- Defined and transparent admission criteria.
- A predefined set of teaching objectives, leading to defined learning outcomes.
- The facilities, infrastructure, leadership and competences available for the support of student learning should be adequate, appropriate and up to date for the training offered.
- Assessment of the students’ achievement in accordance with the agreed learning outcomes of the training offered.
- A system for collecting, assessing and addressing feedback from learners, teachers, technical/administrative staff and programme/course/module managers.
- Availability of appropriate and updated reference material
The substantiation of learning outcomes right after any VSCR module or VSCR course is of elementary importance for quality. In order to measure any gain of competence participants are requested to respond to a set of detailed and predefined questions before and after any module or course.
*) IMI – Innovative Medicines Initative – A European programme supported by the European Commision
**) Klech H, Brooksbank C, Price S, Verpillat P, Bühler FR, Dubois D, Haider N, Johnson C, Lindén HH, Payton T, Renn O & See W. European initiative towards quality standards in education and training for discovery, development and use of medicines. European Journal of Pharmaceutical Sciences 2012; 45: 515-520.